DirectMed Parts is the trusted and knowledgeable source for medical imaging parts and services. Specializing in CT and MRI parts and coils, DirectMed Parts understands the importance of working with service professionals to quickly and accurately deliver quality parts to their customer sites.
Day One Biopharmaceuticals is a clinical-stage biotechnology company that specializes in developing targeted cancer therapies for patients of all ages, with a particular focus on pediatric patients. Recognizing the advancements in cancer research, the company aims to create treatments that can benefit both children and adults diagnosed with genetically defined cancers. Day One Biopharmaceuticals prioritizes the rapid development of therapies to meet the urgent needs of families facing cancer diagnoses. Their lead product candidate, DAY101, is an oral, highly-selective pan-RAF kinase inhibitor designed to penetrate the brain, addressing a significant treatment gap in pediatric oncology. By licensing and acquiring promising products from research institutions and other companies, Day One Biopharmaceuticals strives to bring effective medicines to market for those impacted by cancer.
Curve Beam is a manufacturer that researches and designs cone beam CT imaging equipment for orthopedic specialties.
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cardio-metabolic diseases. The company aims to enhance patient care for individuals with metabolic disorders by addressing the shortcomings of currently available treatments. Its leading product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor designed to effectively lower LDL cholesterol levels while potentially overcoming the limitations associated with existing therapies.
Apollo Intelligence specializes in offering data-driven decision-making solutions for healthcare organizations. The company develops and operates advanced data and insights platforms that leverage technology to enhance health innovation and improve life. By providing access to comprehensive data and analytical tools, Apollo Intelligence assists clients in the life sciences and healthcare sectors with marketing strategies and critical decision-making processes, ultimately promoting operational efficiency.
Pardes Biosciences is a clinical-stage biopharmaceutical company focused on addressing significant health challenges, particularly those posed by viral infections. It utilizes modern reversible-covalent chemistry to discover and develop novel oral drug candidates. The company's lead product candidate, PBI-0451, is an oral antiviral designed to treat and prevent infections from SARS-CoV-2, the virus responsible for COVID-19. By reimagining the patient journey, Pardes aims to provide accessible and convenient treatment options for both adult and pediatric patients, ultimately striving to improve health outcomes and respond effectively to global health crises.
SanReno Therapeutics specializes in the development, manufacturing, and commercialization of therapies for kidney diseases in several regions including the People's Republic of China, Hong Kong, Macau, Taiwan, and Singapore. Established through a joint venture involving Chinook Therapeutics, Frazier Healthcare Partners, and Pivotal bioVenture Partners China, the company is dedicated to researching and producing innovative biotech solutions aimed at improving the quality of life for patients suffering from kidney-related conditions.
Tricida, Inc. is a late-stage pharmaceutical company based in South San Francisco, California, dedicated to the development and commercialization of its lead drug candidate, TRC101. This non-absorbed, orally-administered polymer is designed to treat metabolic acidosis, a condition often associated with chronic kidney disease (CKD). Metabolic acidosis can contribute to the progression of CKD and is linked to various health issues such as muscle wasting, loss of bone density, and increased mortality risk. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101, aiming to provide an effective treatment option for patients suffering from this condition. The company was founded in 2013 and is focused on addressing the unmet medical needs of individuals with CKD.
Silence Therapeutics is a biotechnology company based in London, focused on the discovery, development, and delivery of innovative RNA therapeutics for various medical conditions, including hematology, cardiovascular diseases, and rare metabolic disorders. The company specializes in designing short interfering RNA (siRNA) molecules that activate the RNA interference (RNAi) pathway to selectively degrade target messenger RNAs. Its product pipeline includes SLN124, aimed at treating iron overload disorders, SLN360, which targets cardiovascular diseases associated with elevated lipoprotein levels, and SLN500 for complement-mediated diseases. Silence Therapeutics has established strategic collaborations with AstraZeneca to develop small interfering RNA therapeutics for a range of diseases, and with Genomics England Limited. The company was previously known as SR Pharma before rebranding in 2007.
Scout Bio, Inc. is a biotechnology company focused on developing innovative therapies for chronic health conditions in pets, utilizing veterinary biotechnology and gene therapy. Founded in 2016 and based in Philadelphia, Pennsylvania, the company specializes in creating one-time treatments to address significant issues such as anemia linked to chronic kidney disease in cats. Scout Bio employs Adeno-associated viral vector technology to design and deliver protein and monoclonal antibody therapeutics through single intra-muscular injections. The company's mission is to apply advancements from human medicine to improve veterinary care and enhance the quality of life for pets.
Private Equity Round in 2021
Radionetics Oncology is a biopharmaceutical company dedicated to the discovery and development of innovative radiotherapeutics aimed at treating various oncology indications. The company specializes in creating non-peptide and small molecule agents that facilitate the delivery of therapeutic radioisotopes, targeting solid tumors. By advancing these novel treatments, Radionetics Oncology aims to enhance the options available to medical professionals in combating cancer.
Gritstone bio is a biotechnology company focused on developing personalized immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surfaces of infected cells. This approach leverages the immune system's ability to recognize abnormal cell targets, which is crucial for both anti-tumor and anti-viral immunity. Gritstone bio is building a robust pipeline of immunotherapy product candidates, including GRANITE, SLATE, and CORAL, designed to address various solid tumors. Through these developments, Gritstone bio aims to contribute to the evolving landscape of cancer treatment and enhance patient outcomes.
Alpine Immune Sciences is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the discovery and development of protein-based immunotherapies for cancer, autoimmune, and inflammatory disorders. The company employs a proprietary platform to transform native immune system proteins into multi-targeted therapeutics. Its lead programs include ALPN-101, a dual antagonist targeting the inducible T cell costimulator (ICOS) and CD28 pathways, aimed at treating autoimmune and inflammatory diseases, and ALPN-303, a dual antagonist of the B cell activating factor (BAFF) and the proliferation-inducing ligand (APRIL), which are crucial for B cell activation and survival. Additionally, Alpine has developed ALPN-202, an antagonist targeting programmed cell death protein ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4), designed to enhance cancer treatment. The company also collaborates with Kite Pharma to advance immunotherapy approaches targeting the immune synapse in cancer therapy.
HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines. HilleVax was founded in 2021 and was headquartered in Boston, Massachusetts.
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Its investigational product candidate, IMVT-1401 (formerly known as RVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). We believe that this product has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection.
Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company dedicated to the discovery and development of innovative therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate, paltusotine, is an oral selective nonpeptide somatostatin receptor type 2 biased agonist currently undergoing Phase I clinical trials for the treatment of acromegaly and neuroendocrine tumors. In addition to paltusotine, Crinetics is advancing other candidates, including CRN01941, an oral selective nonpeptide sst2 biased agonist for neuroendocrine tumors, an oral selective somatostatin type 5 receptor agonist for congenital hyperinsulinism, and an oral adrenocorticotropic hormone antagonist targeting Cushing’s disease and congenital adrenal hyperplasia. Founded in 2008 and headquartered in San Diego, California, Crinetics Pharmaceuticals aims to leverage its internal discovery efforts and objective hormonal biomarker endpoints to effectively navigate the development process and bring meaningful treatments to market.
Hummingbird Bioscience focuses on the development of innovative therapeutic antibody-based drugs aimed at addressing significant unmet needs in oncology and immuno-oncology. Utilizing a proprietary rational antibody discovery platform, the company leverages systems biology and computational methods to gain insights into disease mechanisms, guiding the discovery and engineering of new biotherapeutics. Hummingbird's pipeline includes promising drug candidates such as HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, both targeting cancer treatment. The company has formed strategic collaborations with organizations like Cancer Research UK and Amgen and has received a product development grant from the Cancer Prevention and Research Institute of Texas. This collaborative approach enhances Hummingbird's capacity to deliver effective therapies for patients with challenging medical conditions.
ESSA Pharma Inc. is a clinical-stage pharmaceutical company based in Vancouver, Canada, specializing in the development of innovative therapies for prostate cancer. Founded in 2009, the company is currently focusing on EPI-7386, an oral drug candidate undergoing Phase I clinical trials aimed at treating patients with metastatic castration-resistant prostate cancer. ESSA's approach targets the N-terminal domain of the androgen receptor, a critical component for the growth and survival of most prostate cancer cells. By selectively blocking this domain, ESSA aims to advance the next generation of hormone therapies for patients battling advanced prostate cancer.
Seraxis is a biotechnology company founded in March 2013, with operations in Singapore and the United States, and a GMP lab located in Germantown, Maryland. The company specializes in developing innovative cell and encapsulation technologies aimed at creating a practical cell therapy for insulin-dependent diabetes. Their primary objective is to provide a long-term cure for diabetic patients that eliminates the need for immunosuppression, thereby improving the management of glucose levels through the production of insulin. Seraxis is structured to expedite the development of this therapy while maximizing value for its shareholders.
CSafe designs and manufactures cold chain solutions and mobile refrigeration units primarily for the medical device, pharmaceutical, biotechnology, military, and logistics sectors. The company specializes in providing both passive and active containers for shipping temperature-sensitive materials, and it is recognized as a leading provider of active air cargo solutions. In addition to its equipment, CSafe offers a comprehensive range of services, including leasing, active qualification and validation, training, and packaging qualification. With a network of partners, service centers, and distributors, the company serves a diverse customer base domestically and internationally. Established in 1989 and headquartered in Dayton, Ohio, CSafe addresses critical supply chain needs by ensuring the safe transport of temperature-sensitive bio-pharmaceutical cargo.
Aclaris Therapeutics started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies. It is committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. Aclaris is focused on market segments with no FDA-approved medications or where treatment gaps exist.
Sutro Biopharma is a clinical-stage drug discovery, development, and manufacturing company based in South San Francisco, California. The company specializes in creating next-generation protein therapeutics aimed at treating cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Among its product candidates are STRO-001, an antibody-drug conjugate targeting CD74 for patients with multiple myeloma and non-Hodgkin lymphoma, and STRO-002, which is directed against folate receptor-alpha for individuals with ovarian and endometrial cancers. Sutro Biopharma also has a collaboration and licensing agreement with Celgene Corporation to develop bispecific antibodies and antibody-drug conjugates primarily in the field of immuno-oncology. Founded in 2003, the company continues to advance its innovative therapeutic candidates through rigorous clinical development.
Rocket Pharmaceuticals is a biotechnology company dedicated to developing gene therapies aimed at treating rare pediatric diseases. The company's primary focus is on its lead program, a lentiviral-based gene therapy for Fanconi Anemia, a genetic disorder that leads to bone marrow failure. In addition to this, Rocket is advancing therapies for several other conditions, including Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-I, and Infantile Malignant Osteopetrosis, all of which are currently in various stages of clinical and preclinical trials. The company is also engaged in an adeno-associated virus program targeting Danon disease, a serious multi-organ disorder. Rocket Pharmaceuticals collaborates with various academic and research institutions, enhancing its research capabilities and expanding its therapeutic portfolio. The company is based in New York, New York.
Inipharm is a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases.
At Accuity Delivery Systems (ACCDS), we go beyond traditional Clinical Documentation Improvement (CDI) by taking a holistic approach to documenting, coding, & client education. Our services provide a supportive, collaborative and customizable approach to improving clinical documentation and bridging the gap between clinical care and complete, accurate and compliant coding. Specialties: Improved Clinical Documentation, Improved Clinical Documentation, Revenue Recognition Accuracy, Reduced Audit Risk, Improved Quality & Coordination of Care
Scholar Rock is a biotechnology company focused on discovering and developing innovative therapies that target dysregulated growth factors within disease microenvironments. Founded in 2012 and based in Cambridge, Massachusetts, the company employs a proprietary platform to create monoclonal antibodies that selectively modulate the activation of these signaling proteins. This approach aims to avoid traditional challenges associated with growth factor inhibition while facilitating efficient drug development. Scholar Rock's lead product, SRK-015, is designed as a first-in-class inhibitor of myostatin activation, targeting conditions such as spinal muscular atrophy. The company's pipeline includes additional candidates, such as SRK-181, which inhibits latent transforming growth factor beta-1 for cancer treatment. Scholar Rock's research focuses on serious diseases, including neuromuscular disorders, cancer, fibrosis, and autoimmune diseases, reflecting its commitment to transforming patient outcomes through targeted therapies.
Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in developing tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently undergoing a Phase I/Ib clinical trial; it is a TLR8 agonist conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, which is in preclinical development and targets Nectin4, found in bladder, triple-negative breast, head and neck, and non-small cell lung cancers. The company is also developing SBT8230, aimed at treating chronic hepatitis B virus infection, and exploring other agents that utilize its proprietary technology to modulate pathways in oncology and fibrosis indications. Silverback's innovative ImmunoTAC platform enables the design of therapies that are systemically delivered but act specifically at disease sites, unlocking previously inaccessible pathways for treatment.
Trillium Therapeutics Inc. is a clinical-stage immuno-oncology company focused on developing innovative therapies for cancer treatment. The company's lead candidate, TTI-621, is a SIRPaFc fusion protein currently undergoing Phase I clinical trials for advanced relapsed or refractory hematologic malignancies, as well as solid tumors and mycosis fungoides. Another product, TTI-622, is also in Phase I clinical trials and is based on an immunoglobulin G4 SIRPaFc protein. Additionally, Trillium is exploring TTI-10001, a small molecule stimulator of interferon genes agonist in the discovery phase. Founded in 2004 and headquartered in Mississauga, Canada, Trillium Therapeutics has evolved from its previous name, Stem Cell Therapeutics Corp., to focus primarily on harnessing the immune system to combat cancer. The company operates across the United States and Canada, emphasizing the development of targeted protein therapeutics.
MBX Biosciences, Inc. is a biotechnology company based in Carmel, Indiana, specializing in the development of therapeutics for rare endocrine disorders. Established in 2018, the company focuses on creating peptides aimed at treating genetic diseases that affect glandular hormones, which play a crucial role in the body’s chemical messaging system. By targeting conditions with inadequate treatment options, MBX Biosciences is dedicated to discovering, developing, and commercializing innovative endocrine therapeutics.
Lassen Therapeutics specializes in developing monoclonal antibodies aimed at treating fibrosis, rare diseases, and oncology. The company’s primary candidate, LASN01, targets the IL-11 receptor alpha, a critical component in the IL-6 family of cytokines. IL-11 is a significant mediator of fibrosis and plays an essential role in tumor growth and the organization of the tumor microenvironment. By blocking IL-11's activity, Lassen Therapeutics seeks to provide more effective treatment options compared to traditional approaches that target other factors like TGF-β and CTGF. Through innovative antibody technologies, the company aims to deliver breakthrough therapeutics that improve the lives of patients facing serious health challenges.
Lengo Therapeutics is a biopharmaceutical company dedicated to the discovery and development of cancer treatments, specifically focusing on precision therapeutics that target driver mutations in oncology. The company identifies various mutations in cancers that have not been adequately addressed by current therapies, thereby assisting medical practitioners and pharmaceutical companies in meeting the unmet needs in cancer treatment. Lengo's efforts include the development of late-preclinical small molecule drugs aimed at multiple solid tumor types, enhancing the ability to address specific oncological challenges.
Dascena, Inc. is a healthcare technology company based in Oakland, California, that specializes in developing machine learning algorithms aimed at enhancing patient care and early disease intervention. Founded in 2018, Dascena focuses on creating algorithmic software that processes electronic health record data to predict critical conditions such as acute decompensation, sepsis, and acute kidney injury. By leveraging extensive clinical research, the company provides tools that support clinical decision-making, facilitate point-of-care diagnostics, and serve as biopharma companion diagnostics. Dascena's innovations address significant unmet healthcare needs, ultimately aiming to improve care outcomes and save lives through timely and accurate interventions.
Aspen Neuroscience, Inc. is a biotechnology company focused on developing induced pluripotent stem cells (iPSCs) to create patient-specific therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018 and based in San Diego, California, the company is advancing its pipeline of products, which includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited autologous neuron replacement therapy targeting familial forms of the disease. Aspen Neuroscience employs innovative genomic approaches in conjunction with stem cell biology to address diseases with significant unmet medical needs, aiming to provide restorative cell therapies that can modify the progression of Parkinson's disease and potentially extend to other affected organs.
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, specializing in the discovery and development of biologic therapeutics for cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create differentiated therapeutic compounds with unique mechanisms of action. Its lead drug candidate, MT-3724, is undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing MT-4019, which targets CD38, and has established collaborations with Takeda Pharmaceutical Company to advance CD38-targeted therapies for conditions like multiple myeloma, as well as with Vertex Pharmaceuticals to enhance hematopoietic stem cell transplant processes. The company’s pipeline also includes other candidates such as MT-6402, MT-8421, and MT-0169.
Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases globally. The company’s lead candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine. Additionally, Vaxcyte is advancing VAX-XP, which targets emerging strains that contribute to invasive pneumococcal disease and antibiotic resistance. Other notable candidates include VAX-A1, designed to protect against Group A Streptococcus infections, and VAX-PG, a therapeutic vaccine aimed at treating periodontal disease caused by Porphyromonas gingivalis. Vaxcyte utilizes a proprietary cell-free protein synthesis platform that enables the creation of protein carriers and antigens, enhancing vaccine development beyond conventional methods. Founded in 2013 and headquartered in Foster City, California, the company was previously known as SutroVax, Inc. before rebranding in May 2020.
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focused on developing therapies for cancer treatment. The company's lead product, entinostat, is a class I HDAC inhibitor currently in Phase III clinical trials for advanced hormone receptor positive, HER2 negative breast cancer. Additionally, entinostat is being tested in combination with Keytruda and Tecentriq in Phase Ib/II trials for non-small cell lung cancer and metastatic breast cancer. Another significant candidate, SNDX-5613, is a selective inhibitor targeting the Menin-MLL interaction, undergoing Phase I/II trials for acute leukemias. The company is also developing SNDX-6352, a monoclonal antibody for chronic graft versus host disease, currently in Phase I/II trials. Syndax has established collaborations with major pharmaceutical companies and research organizations, enhancing its research and development capabilities. Founded in 2005, Syndax Pharmaceuticals aims to address critical needs in oncology through innovative therapeutic approaches.
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Irvine, California, that specializes in the development and commercialization of innovative therapeutic candidates for ophthalmic conditions. Its primary focus is on TP-03, a novel treatment currently in Phase IIb/III trials for blepharitis caused by Demodex mite infestations, as well as meibomian gland disease. The company is also advancing additional candidates, including TP-04 for rosacea and TP-05 for Lyme disease prophylaxis and community malaria reduction. Tarsus aims to address significant unmet medical needs in various therapeutic areas, initially concentrating on eye care where treatment options are limited. Founded in 2016, Tarsus Pharmaceuticals continues to expand its pipeline to include diverse diseases across different medical fields.
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, dedicated to developing innovative therapies that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic currently undergoing Phase III clinical trials for the treatment of severe oral mucositis induced by radiation in patients with head and neck cancer. Additionally, it is being tested in Phase IIa trials for radiotherapy-induced esophagitis in lung cancer patients. Galera is also advancing a second candidate, GC4711, which is in Phase I/II trials targeting pancreatic and lung cancers. The company was founded in 2012 and is committed to addressing severe side effects associated with cancer treatments to improve patient outcomes.
REGENXBIO Inc. is a clinical-stage biotechnology company specializing in gene therapy aimed at addressing genetic defects and enabling cells to produce therapeutic proteins and antibodies. The company utilizes its proprietary NAV Technology Platform, which involves recombinant adeno-associated virus vectors for gene delivery. REGENXBIO’s lead candidate, RGX-314, is currently in Phase I/IIa clinical trials for the treatment of wet age-related macular degeneration. Additional product candidates under development include RGX-121 for mucopolysaccharidosis type II, RGX-111 for mucopolysaccharidosis type I, RGX-181 for late infantile neuronal ceroid lipofuscinosis type II, and RGX-501 for homozygous familial hypercholesterolemia. Beyond its own product candidates, REGENXBIO also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies and has a collaboration agreement with Neurimmune AG to develop vectorized antibodies for neurodegenerative diseases. Founded in 2008 and headquartered in Rockville, Maryland, the company was previously known as ReGenX Biosciences, LLC before rebranding in 2014.
IVERIC bio is a biopharmaceutical company dedicated to discovering and developing innovative treatment options for retinal diseases that have significant unmet medical needs. The company is actively working on therapeutic product candidates aimed at age-related retinal diseases, as well as gene therapy product candidates designed for orphan inherited retinal diseases. Through its focused research and development efforts, IVERIC bio seeks to address critical gaps in the treatment landscape for patients suffering from these conditions.
Epizyme, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery, development, and commercialization of novel epigenetic medicines for cancer and other serious diseases. The company has developed Tazemetostat, an EZH2 inhibitor approved for the treatment of metastatic or locally advanced epithelioid sarcoma in the United States. Additionally, Tazemetostat is being investigated in combination therapies for various cancers, including relapsed follicular lymphoma and high-risk diffuse large B-cell lymphoma, as well as in patients with platinum-resistant solid tumors and castration-resistant prostate cancer. Epizyme also works on other product candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, along with inhibitors targeting PRMT5 and PRMT1 for different types of cancers. Established in 2007, Epizyme collaborates with several prominent organizations to advance its research and development efforts.
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. Founded in 2016 and based in Westlake Village, California, the company is focused on addressing unmet medical needs within the field of immuno-dermatology. Its lead product candidate, a topical cream formulation of roflumilast known as ARQ-151, is undergoing Phase III clinical trials for plaque psoriasis and atopic dermatitis. Additionally, Arcutis is working on several other candidates, including ARQ-154, a topical foam for seborrheic dermatitis and scalp psoriasis, ARQ-252, a selective inhibitor for hand eczema and other inflammatory conditions, and ARQ-255, designed to penetrate deeper into the skin for alopecia areata treatment. The company aims to leverage advances in immunology and inflammation to create effective therapies for challenging skin diseases.
Passage Bio is a fully integrated gene therapy company with a mission to develop a portfolio of five life-transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program (GTP) as well as the Orphan Disease Center (ODC). Pursuant to the research collaboration, GTP conducts IND-enabling preclinical work, and Passage Bio is responsible for clinical development, regulatory, manufacturing and commercialization of all product candidates. The ODC is responsible for natural history studies, KOL engagement, and patient advocacy outreach.
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Buffalo Grove, Illinois, focused on developing and commercializing innovative treatments for gastrointestinal diseases. Established in 2018 and launched in 2019, the company is advancing its lead drug candidate, vonoprazan, a potassium-competitive acid blocker (P-CAB) that effectively inhibits acid secretion in the stomach. Vonoprazan is currently undergoing Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease and is also being studied in combination with antibiotics for the treatment of Helicobacter pylori infection. The company aims to address significant unmet medical needs in patients suffering from acid-related disorders and has assembled a team of experts in the gastrointestinal and pharmaceutical fields to drive its development efforts.
CPS is a hospital solutions provider that specializes in enhancing operations and supporting patient care within healthcare organizations. Previously known as Comprehensive Pharmacy Services, CPS offers a range of services, including inpatient pharmacy management, telepharmacy, consulting, and outpatient pharmacy management. By delivering expert technology solutions and tailored support, CPS assists hospitals and health systems in addressing various challenges while improving financial and clinical performance. The company's focus on empowering healthcare organizations aims to advance the standard of care and enhance patient satisfaction.
Scout Bio, Inc. is a biotechnology company focused on developing innovative therapies for chronic health conditions in pets, utilizing veterinary biotechnology and gene therapy. Founded in 2016 and based in Philadelphia, Pennsylvania, the company specializes in creating one-time treatments to address significant issues such as anemia linked to chronic kidney disease in cats. Scout Bio employs Adeno-associated viral vector technology to design and deliver protein and monoclonal antibody therapeutics through single intra-muscular injections. The company's mission is to apply advancements from human medicine to improve veterinary care and enhance the quality of life for pets.
Imago BioSciences is a clinical-stage biotechnology company based in Redwood City, California, that specializes in developing innovative medicines for hematologic diseases. Founded in 2012, the company focuses on therapeutics that target genetic and epigenetic factors, specifically through the inhibition of lysine-specific demethylase 1 (LSD1), an enzyme crucial in blood cell production. Imago BioSciences aims to address significant medical challenges associated with conditions such as leukemia, myelodysplastic syndrome, and other bone marrow disorders. Its lead product candidate, Bomedemstat, is an orally available small molecule designed to treat certain myeloproliferative neoplasms, with the goal of altering disease progression and improving the quality and longevity of patients' lives.
Passage Bio is a fully integrated gene therapy company with a mission to develop a portfolio of five life-transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program (GTP) as well as the Orphan Disease Center (ODC). Pursuant to the research collaboration, GTP conducts IND-enabling preclinical work, and Passage Bio is responsible for clinical development, regulatory, manufacturing and commercialization of all product candidates. The ODC is responsible for natural history studies, KOL engagement, and patient advocacy outreach.
Recida Therapeutics is a biotechnology company focused on developing innovative antibiotic drugs to combat serious infections caused by antibiotic-resistant bacteria. The company's primary aim is to create novel-class antibiotics that specifically target multi-drug resistant gram-negative bacteria, which pose significant health risks to patients. By addressing the growing challenge of antibiotic resistance, Recida Therapeutics seeks to provide effective therapeutic options for individuals facing potentially life-threatening infections.
Alpine Immune Sciences is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the discovery and development of protein-based immunotherapies for cancer, autoimmune, and inflammatory disorders. The company employs a proprietary platform to transform native immune system proteins into multi-targeted therapeutics. Its lead programs include ALPN-101, a dual antagonist targeting the inducible T cell costimulator (ICOS) and CD28 pathways, aimed at treating autoimmune and inflammatory diseases, and ALPN-303, a dual antagonist of the B cell activating factor (BAFF) and the proliferation-inducing ligand (APRIL), which are crucial for B cell activation and survival. Additionally, Alpine has developed ALPN-202, an antagonist targeting programmed cell death protein ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4), designed to enhance cancer treatment. The company also collaborates with Kite Pharma to advance immunotherapy approaches targeting the immune synapse in cancer therapy.
Sojournix, Inc. is a biotechnology company developing innovative medicines for women's health and endocrine disorders.
Atlanta Gastroenterology Associates is one of the gastroenterology practices in the country dedicated to the detection and treatment of digestive and liver diseases, as well as colon cancer.
Mirum Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing therapies for serious liver diseases. Founded in 2018 and based in Foster City, California, the company focuses on addressing rare and orphan diseases. Its lead product candidate, maralixibat, is an investigational oral drug currently in Phase 3 clinical trials for treating progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS), and biliary atresia. Additionally, Mirum is developing volixibat, aimed at treating intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. The company’s commitment to innovative therapies positions it as a key player in the biopharmaceutical landscape dedicated to improving the lives of patients with debilitating liver conditions.
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. Founded in 2016 and based in Westlake Village, California, the company is focused on addressing unmet medical needs within the field of immuno-dermatology. Its lead product candidate, a topical cream formulation of roflumilast known as ARQ-151, is undergoing Phase III clinical trials for plaque psoriasis and atopic dermatitis. Additionally, Arcutis is working on several other candidates, including ARQ-154, a topical foam for seborrheic dermatitis and scalp psoriasis, ARQ-252, a selective inhibitor for hand eczema and other inflammatory conditions, and ARQ-255, designed to penetrate deeper into the skin for alopecia areata treatment. The company aims to leverage advances in immunology and inflammation to create effective therapies for challenging skin diseases.
Cirius Therapeutics, Inc. is a clinical-stage pharmaceutical company dedicated to developing and commercializing therapies for liver and metabolic diseases. Founded in 2015 and headquartered in San Diego, California, the company focuses on its lead product candidate, MSDC-0602K, an oral small molecule currently undergoing Phase 2b clinical trials for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis. This next-generation insulin sensitizer aims to address the underlying pathophysiology of NASH, a condition characterized by fat accumulation and inflammation in the liver that can lead to severe complications such as cirrhosis and liver cancer. Cirius Therapeutics is committed to providing innovative solutions to healthcare providers for managing liver and metabolic diseases.
Krystal Biotech is a biopharmaceutical company using gene therapy to develop best in class treatments that provide significant clinical benefit for patients suffering from rare debilitating disorders.
Millendo Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for endocrine diseases resulting from hormone dysregulation. The company focuses on addressing significant unmet medical needs by creating distinct therapies that improve clinical care. By leveraging scientific advancements, Millendo aims to develop novel compounds that can effectively treat complex conditions, ultimately enhancing the quality of life for patients, families, and caregivers.
ARMO BioSciences, Inc. is an immuno-oncology company based in Redwood City, California, focused on developing biologic therapeutics that stimulate the immune system to combat cancer. The company's product pipeline includes several innovative candidates, such as AM0010, a long-acting form of interleukin-10 that enhances immune response, and AM0001, an anti-PD-1 monoclonal antibody targeting various cancers. Other key products in development include an anti-LAG-3 checkpoint inhibitor, AM0015, a recombinant form of interleukin-15, and AM0012, a recombinant interleukin-12. Established in 2010 and formerly known as Targenics, ARMO BioSciences aims to activate and enhance the body's immune response against tumors, thereby improving outcomes for cancer patients. As of mid-2018, it operates as a subsidiary of Eli Lilly and Company.
Mavupharma Inc., founded in 2016 and headquartered in the United States, focuses on developing non-nucleotide, conditional modulators of the STING pathway to address cancer and infectious diseases. As a subsidiary of AbbVie Inc. since July 2019, the company utilizes small molecules to indirectly modulate the STING pathway, harnessing the innate immune system. This approach aims to provide effective oral treatments for cancer patients, enhancing therapeutic options within the medical community.
Outpost Medicine, founded in 2016 and based in the United States, focuses on developing innovative therapeutics for urologic and gynecologic diseases and disorders. The company is dedicated to addressing gastrointestinal and urologic conditions, with its lead clinical-stage product candidate, OP-233, aimed at treating stress urinary incontinence (SUI), a condition characterized by involuntary urine loss during physical activities. Additionally, Outpost is working on treatments for overactive bladder (OAB) and irritable bowel syndrome (IBS), reflecting its commitment to advancing healthcare solutions in these areas.
Southside Pharmacy is a pharmacy that offers medicine sales, blood glucose testing, and surgical and fitness equipment hire services.
Gritstone bio is a biotechnology company focused on developing personalized immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surfaces of infected cells. This approach leverages the immune system's ability to recognize abnormal cell targets, which is crucial for both anti-tumor and anti-viral immunity. Gritstone bio is building a robust pipeline of immunotherapy product candidates, including GRANITE, SLATE, and CORAL, designed to address various solid tumors. Through these developments, Gritstone bio aims to contribute to the evolving landscape of cancer treatment and enhance patient outcomes.
Private Equity Round in 2017
Alteon Health will advance healthcare through patient-focused care, physician-led innovation, data-driven practices, and best-in-class healthcare partnerships
Iterum Therapeutics plc is a clinical-stage pharmaceutical company focused on developing anti-infective therapies to address multi-drug resistant pathogens. Headquartered in Dublin, Ireland, the company is advancing its lead product, sulopenem, a novel penem compound available in both oral and intravenous formulations. Currently in Phase III clinical trials, sulopenem is being evaluated for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum aims to provide effective solutions to combat antibiotic resistance, particularly against a range of gram-negative, gram-positive, and anaerobic bacteria that are resistant to existing antibiotics. Founded in 2015, Iterum Therapeutics seeks to improve the lives of patients affected by serious and life-threatening infections globally.
Cirius Therapeutics, Inc. is a clinical-stage pharmaceutical company dedicated to developing and commercializing therapies for liver and metabolic diseases. Founded in 2015 and headquartered in San Diego, California, the company focuses on its lead product candidate, MSDC-0602K, an oral small molecule currently undergoing Phase 2b clinical trials for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis. This next-generation insulin sensitizer aims to address the underlying pathophysiology of NASH, a condition characterized by fat accumulation and inflammation in the liver that can lead to severe complications such as cirrhosis and liver cancer. Cirius Therapeutics is committed to providing innovative solutions to healthcare providers for managing liver and metabolic diseases.
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. Founded in 2016 and based in Westlake Village, California, the company is focused on addressing unmet medical needs within the field of immuno-dermatology. Its lead product candidate, a topical cream formulation of roflumilast known as ARQ-151, is undergoing Phase III clinical trials for plaque psoriasis and atopic dermatitis. Additionally, Arcutis is working on several other candidates, including ARQ-154, a topical foam for seborrheic dermatitis and scalp psoriasis, ARQ-252, a selective inhibitor for hand eczema and other inflammatory conditions, and ARQ-255, designed to penetrate deeper into the skin for alopecia areata treatment. The company aims to leverage advances in immunology and inflammation to create effective therapies for challenging skin diseases.
Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases globally. The company’s lead candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine. Additionally, Vaxcyte is advancing VAX-XP, which targets emerging strains that contribute to invasive pneumococcal disease and antibiotic resistance. Other notable candidates include VAX-A1, designed to protect against Group A Streptococcus infections, and VAX-PG, a therapeutic vaccine aimed at treating periodontal disease caused by Porphyromonas gingivalis. Vaxcyte utilizes a proprietary cell-free protein synthesis platform that enables the creation of protein carriers and antigens, enhancing vaccine development beyond conventional methods. Founded in 2013 and headquartered in Foster City, California, the company was previously known as SutroVax, Inc. before rebranding in May 2020.
Private Equity Round in 2017
Recognized as the number one orthopedic group since 2012 by Ranking Arizona, The CORE Institute, was founded to fulfill a vision of excellence in patient care encompassing the entire spectrum of musculoskeletal and neurosciences care. Consistent with our mission, The CORE Institute delivers the best in musculoskeletal and neurological care, built upon a foundation of pioneering research, academics, community service, and a passion for excellence in patient care. It is now one of the premier patient care destinations in the World and cares for patients from around the globe.
Matrix Medical Network specializes in providing health risk assessments and care management services primarily for Medicare Advantage plans. The company conducts in-home evaluations through a national network of licensed Nurse Practitioners (NPs), who perform comprehensive, non-invasive health assessments. These assessments include physical examinations, inquiries about personal and family medical history, and reviews of the living environment and medications. Matrix aims to identify potential health risks that may require further medical attention, offering recommendations and health information during each visit. Established in 2001, the company has grown to become one of the largest providers of prospective health assessments in the United States, completing over 224,000 assessments in 2012 alone. Headquartered in Scottsdale, Arizona, with a member outreach center in Clearwater, Florida, Matrix operates across more than 30 states and is owned by Welsh, Carson, Anderson & Stowe.
Alpine Immune Sciences is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the discovery and development of protein-based immunotherapies for cancer, autoimmune, and inflammatory disorders. The company employs a proprietary platform to transform native immune system proteins into multi-targeted therapeutics. Its lead programs include ALPN-101, a dual antagonist targeting the inducible T cell costimulator (ICOS) and CD28 pathways, aimed at treating autoimmune and inflammatory diseases, and ALPN-303, a dual antagonist of the B cell activating factor (BAFF) and the proliferation-inducing ligand (APRIL), which are crucial for B cell activation and survival. Additionally, Alpine has developed ALPN-202, an antagonist targeting programmed cell death protein ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4), designed to enhance cancer treatment. The company also collaborates with Kite Pharma to advance immunotherapy approaches targeting the immune synapse in cancer therapy.
Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. This mechanism has applicability across a number of CNS disorders. Our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need.
Entasis Therapeutics is a late-stage clinical biopharmaceutical company dedicated to developing innovative treatments for serious infections caused by multidrug-resistant Gram-negative bacteria, a growing global health concern. The company’s anti-infective discovery platform has led to a diverse pipeline of differentiated drug candidates, including ETX2514SUL and SUL-DUR, which target Acinetobacter baumannii, zoliflodacin for Neisseria gonorrhoeae, and ETX0282CPDP aimed at Enterobacterales. Additionally, ETX0462 is being developed to address infections caused by Pseudomonas. Through its focused efforts, Entasis Therapeutics aims to provide effective solutions for patients suffering from these challenging bacterial infections.
Zavante Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative treatments for patients in hospital settings. The company's primary focus is on ZOLYD, an investigational injectable antibiotic designed to address serious and life-threatening infections, including those caused by multi-drug resistant gram-negative and gram-positive bacteria. Incorporated in 2013, Zavante aims to enhance patient outcomes through its novel therapeutic approaches. As of July 2018, it operates as a subsidiary of Nabriva Therapeutics plc.
Iterum Therapeutics plc is a clinical-stage pharmaceutical company focused on developing anti-infective therapies to address multi-drug resistant pathogens. Headquartered in Dublin, Ireland, the company is advancing its lead product, sulopenem, a novel penem compound available in both oral and intravenous formulations. Currently in Phase III clinical trials, sulopenem is being evaluated for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum aims to provide effective solutions to combat antibiotic resistance, particularly against a range of gram-negative, gram-positive, and anaerobic bacteria that are resistant to existing antibiotics. Founded in 2015, Iterum Therapeutics seeks to improve the lives of patients affected by serious and life-threatening infections globally.
Outpost Medicine, founded in 2016 and based in the United States, focuses on developing innovative therapeutics for urologic and gynecologic diseases and disorders. The company is dedicated to addressing gastrointestinal and urologic conditions, with its lead clinical-stage product candidate, OP-233, aimed at treating stress urinary incontinence (SUI), a condition characterized by involuntary urine loss during physical activities. Additionally, Outpost is working on treatments for overactive bladder (OAB) and irritable bowel syndrome (IBS), reflecting its commitment to advancing healthcare solutions in these areas.
Millendo Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for endocrine diseases resulting from hormone dysregulation. The company focuses on addressing significant unmet medical needs by creating distinct therapies that improve clinical care. By leveraging scientific advancements, Millendo aims to develop novel compounds that can effectively treat complex conditions, ultimately enhancing the quality of life for patients, families, and caregivers.
Allena Pharmaceuticals is a late-stage clinical biopharmaceutical company based in Newton, Massachusetts, that specializes in developing and commercializing oral enzyme therapeutics for rare and severe metabolic and kidney disorders. The company's primary focus is on conditions that involve the excessive accumulation of metabolites such as oxalate and urate, which can lead to complications like kidney stones and chronic kidney disease. Allena's lead product candidate, reloxaliase, is currently undergoing a pivotal Phase 3 clinical program aimed at treating enteric hyperoxaluria, a disorder linked to significantly high urinary oxalate levels. Additionally, the company is developing ALLN-346, a novel enzyme designed to address hyperuricemia in patients with moderate to severe chronic kidney diseases. Allena Pharmaceuticals aims to provide innovative treatments that address unmet medical needs in these patient populations.
Gritstone bio is a biotechnology company focused on developing personalized immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surfaces of infected cells. This approach leverages the immune system's ability to recognize abnormal cell targets, which is crucial for both anti-tumor and anti-viral immunity. Gritstone bio is building a robust pipeline of immunotherapy product candidates, including GRANITE, SLATE, and CORAL, designed to address various solid tumors. Through these developments, Gritstone bio aims to contribute to the evolving landscape of cancer treatment and enhance patient outcomes.
Calibrium is a privately-held biopharmaceutical company dedicated to the development of innovative drug candidates aimed at treating diabetes and related metabolic disorders. Co-founded by Fritz French, who serves as Chief Executive Officer, and Richard DiMarchi, PhD, the Chief Scientific Officer, Calibrium focuses on creating a diverse portfolio of therapeutic solutions to address the growing challenges posed by these conditions.
AnaptysBio is a privately-held therapeutic antibody product company that uses of somatic hypermutation, or SHM, for antibody discovery and optimization. SHM is the body's natural process for generating potent antibodies to fight disease. The Company's SHM-Platform utilizes the key components of SHM and other techniques to generate antibodies for therapeutic applications through an iterative process of natural evolution and high-throughput selection a process that has been referred to as naturalizing antibodies. This versatile platform can be used both to discover and optimize antibodies directed at specific disease targets and also affinity mature existing antibodies to improve their binding properties. In addition to providing a more powerful approach to antibody discovery and protein optimization, it addresses a growing void in the therapeutic antibody field due to a string of acquisitions and licensing deals that have reduced the availability of many technologies.
Collegium Pharmaceutical is a specialty pharmaceutical company that develops and commercializes products aimed at addressing pain management while mitigating the risks of prescription drug abuse. The company utilizes its proprietary DETERx platform technology, which ensures that its formulations maintain extended-release and safety profiles even when subjected to common methods of misuse such as chewing or crushing. Collegium's product lineup includes Xtampza ER, an abuse-deterrent, extended-release oral formulation of oxycodone, and Nucynta products, which consist of both extended-release and immediate-release formulations of tapentadol. These offerings are designed to manage chronic pain and provide effective treatment solutions while incorporating tamper-resistant features to combat non-medical use. Headquartered in Stoughton, Massachusetts, Collegium Pharmaceutical was incorporated in 2002 and has focused on building a portfolio of innovative products that align with evolving patient needs and regulatory standards.
Merganser Biotech, Inc. is a research and development company focused on creating innovative medicines for the treatment of rare hematological and iron overload diseases, such as hemochromatosis, polycythemia vera, acute severe infections, and beta thalassemia. The company specializes in the development of hepcidin mimetic peptides, which are designed to regulate iron metabolism and address ineffective erythropoiesis. Founded in 2011, Merganser Biotech is headquartered in King of Prussia, Pennsylvania.
ChanRx Corp. intends to develop and market small molecule pharmaceuticals to treat atrial fibrillation, a common arrhythmia that can cause heart attacks and strokes. The company was founded in 2008 and is based in Cleveland, Ohio.
Cidara Therapeutics is a biotechnology company based in San Diego, California, established in 2012. The company specializes in the discovery and development of innovative anti-infective therapies for serious diseases, particularly those that affect individuals with compromised immune systems. Its lead candidate, rezafungin acetate, is an antifungal agent designed to treat and prevent severe invasive fungal infections, such as candidemia and invasive candidiasis, which carry significant mortality risks. In addition to its antifungal efforts, Cidara is advancing its proprietary Cloudbreak platform, which focuses on developing antiviral Fc-conjugates aimed at preventing and treating various viral infections, including influenza, RSV, HIV, and coronavirus. Cidara's mission is to transform treatment and prevention strategies for life-threatening illnesses.
Allena Pharmaceuticals is a late-stage clinical biopharmaceutical company based in Newton, Massachusetts, that specializes in developing and commercializing oral enzyme therapeutics for rare and severe metabolic and kidney disorders. The company's primary focus is on conditions that involve the excessive accumulation of metabolites such as oxalate and urate, which can lead to complications like kidney stones and chronic kidney disease. Allena's lead product candidate, reloxaliase, is currently undergoing a pivotal Phase 3 clinical program aimed at treating enteric hyperoxaluria, a disorder linked to significantly high urinary oxalate levels. Additionally, the company is developing ALLN-346, a novel enzyme designed to address hyperuricemia in patients with moderate to severe chronic kidney diseases. Allena Pharmaceuticals aims to provide innovative treatments that address unmet medical needs in these patient populations.
Imago BioSciences is a clinical-stage biotechnology company based in Redwood City, California, that specializes in developing innovative medicines for hematologic diseases. Founded in 2012, the company focuses on therapeutics that target genetic and epigenetic factors, specifically through the inhibition of lysine-specific demethylase 1 (LSD1), an enzyme crucial in blood cell production. Imago BioSciences aims to address significant medical challenges associated with conditions such as leukemia, myelodysplastic syndrome, and other bone marrow disorders. Its lead product candidate, Bomedemstat, is an orally available small molecule designed to treat certain myeloproliferative neoplasms, with the goal of altering disease progression and improving the quality and longevity of patients' lives.
VentiRx Pharmaceuticals is a clinical stage biopharmaceutical company based in Seattle, Washington, focused on developing and commercializing immunotherapies targeting Toll-like Receptor 8 (TLR8) for the treatment of cancer, respiratory, and inflammatory diseases. Founded in 2006, the company’s lead investigational drug, Motolimod, works by mobilizing the patient's immune system to fight cancer through the activation of myeloid dendritic cells, monocytes, and natural killer cells. VentiRx's product pipeline includes VTX-2337, a TLR8 agonist aimed at enhancing immune responses against solid tumors and specific cancers such as ovarian and breast cancer, as well as VTX-1463, designed to address allergies. The company is also exploring TLR8 antagonists for autoimmune diseases and compounds intended as vaccine adjuvants. VentiRx Pharmaceuticals operates as a subsidiary of Celgene Corporation and has additional operations in San Diego.
Cidara Therapeutics is a biotechnology company based in San Diego, California, established in 2012. The company specializes in the discovery and development of innovative anti-infective therapies for serious diseases, particularly those that affect individuals with compromised immune systems. Its lead candidate, rezafungin acetate, is an antifungal agent designed to treat and prevent severe invasive fungal infections, such as candidemia and invasive candidiasis, which carry significant mortality risks. In addition to its antifungal efforts, Cidara is advancing its proprietary Cloudbreak platform, which focuses on developing antiviral Fc-conjugates aimed at preventing and treating various viral infections, including influenza, RSV, HIV, and coronavirus. Cidara's mission is to transform treatment and prevention strategies for life-threatening illnesses.
Sierra Oncology, Inc. is a clinical-stage biopharmaceutical company that focuses on developing and commercializing therapies for patients with hematology and oncology needs. The company's lead drug candidate, momelotinib, is an orally bioavailable inhibitor targeting JAK1, JAK2, and ACVR1, which has undergone two completed Phase 3 trials for myelofibrosis treatment. Additionally, Sierra Oncology is advancing SRA737, a small molecule inhibitor of Checkpoint kinase 1 currently in Phase 1/2 clinical trials, and SRA141, an inhibitor of cell division cycle 7 kinase, which is in preclinical development. Founded in 2003 and headquartered in Vancouver, Canada, Sierra Oncology aims to provide targeted therapies for rare forms of cancer, leveraging scientific expertise to address limitations in existing treatments and improve patient outcomes. The company was previously known as ProNAi Therapeutics, Inc. before its name change in January 2017.
PowerVision, Inc. is a company that specializes in the development of innovative intraocular lenses aimed at restoring vision for individuals suffering from presbyopia and cataracts. Founded in 2002 and based in Belmont, California, PowerVision has created the FluidVision accommodating intraocular lens, which utilizes a unique fluid-controlled mechanism to mimic the natural function of a healthy eye. This technology allows users to dynamically adjust their focus for clear vision at all distances, potentially liberating millions from the need for glasses or other vision correction methods. The FluidVision lens is designed to meet the clinical and lifestyle needs of patients, offering a significant advancement in vision correction surgery. PowerVision's approach addresses the visual impairments faced by over 20 million people in the United States with cataracts and more than 90 million individuals affected by presbyopia, particularly those in their 40s and 50s.
Ignyta, Inc. is a biotechnology company focused on discovering, developing, and commercializing targeted therapies for cancer treatment. Based in San Diego, California, Ignyta specializes in molecularly targeted therapies aimed at eradicating residual diseases and improving patient outcomes. The company's key products include entrectinib, a tyrosine kinase inhibitor that targets specific proteins associated with various cancers, and RXDX-105, which is designed to treat RET-driven solid tumors. Additionally, Ignyta emphasizes the integration of companion diagnostics to better match therapies with patients likely to benefit from them. Founded in 2011, the company operates as a subsidiary of Roche Holdings, Inc., underscoring its commitment to advancing precision medicine in oncology.
PreCision Dermatology is a fully-integrated dermatology company focused on delivering innovative therapies that enhance skin care for both doctors and patients. The company specializes in developing dermatological products, including a drug delivery platform designed to improve the efficacy of active ingredients while minimizing side effects and enhancing the natural skin barrier. This technology enables the treatment of various dermatological conditions, such as atopic dermatitis, acne, and rosacea. PreCision Dermatology is experiencing rapid growth through a combination of internal innovation, acquisitions, in-licensing, and co-marketing strategies, positioning itself as a key player in the skincare industry.